CHMP positive opinion is based on results from the Phase 3 SELECT-AXIS 2 study showing upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 response at week 14 versus placebo1 Non-radiographic axial spondyloarthritis (nr-axSpA) is part of the axial spondyloarthritis (axSpA) spectrum…